

PROVIDER N. 157

GISEA/OEG INTERNATIONAL SYMPOSIUM 2026

Rheumatology and complex diseases: next steps to the future

20-22 Maggio 2026

Sala Convegni Palazzo San Giorgio - Trani

PROGRAMMA SCIENTIFICO

Board Scientifico

- Roberto Caporali
- Fabrizio Conti
- Florenzo Iannone
- Fabiola Atzeni
- Elisa Gremese
- Marco Sebastiani
- Ennio Giulio Favalli

Razionale

This congress is devised to address the evolving landscape of rheumatology by focusing on several key strategic themes:

Complexity and Precision Medicine

The meeting emphasizes moving beyond traditional classification toward understanding disease complexity and heterogeneity. Multiple sessions focus on disease interception and prevention (PsA screening in psoriasis patients), subgroup identification in systemic sclerosis, mechanism-driven approaches in vasculitis, precision care in SLE and vasculitis

Personalized Treatment Strategies. Rather than one-size-fits-all approaches, the program explores how different factors should drive therapeutic decisions, such as synovitis-driven therapy in rheumatoid arthritis, serology-driven therapy considerations, comorbidity-driven therapy adaptations

Emerging Therapeutic Frontiers. The congress explores novel targeted therapies (particularly for Sjögren's and systemic sclerosis), artificial intelligence applications in myositis, new drugs for obesity management in rheumatic diseases

Critical Comorbidities. Dedicated attention to factors that complicate management, namely obesity and its impact on treatment, interstitial lung disease in RA, infections and prophylaxis in immunocompromised patients, post-COVID considerations

Pathogenetic Understanding. Emphasis on mechanisms linking related conditions (skin psoriasis to PsA) and evolving therapeutic targets (B cells in SLE).

Targeted Therapies Reshaping Clinical Practice

- ◇ Sjögren's Syndrome "Rethinking nomenclature in the era of targeted therapies" acknowledges that new treatments (likely anti-CD40, ianalumab, others) are changing how we conceptualize and classify the disease. Understanding which patients benefit from which targeted approaches
- ◇ Systemic Sclerosis. "Novel therapeutics and subgroup insights" reflects the emergence of multiple new treatment options (anti-fibrotics, immunomodulators, vascular therapies). Recognition that SSc is not one disease but multiple phenotypes requiring different interventions. Integration of organ-specific and systemic approaches
- ◇ Myositis. "On the brink of a revolution" with JAK inhibitors and other targeted therapies. Artificial Intelligence integration: Representing the cutting edge where machine learning aids in diagnosis, classification, treatment prediction, and outcome assessment. Moving from broad immunosuppression to targeted pathway inhibition
- ◇ SLE. "B cells reloaded" suggests evolution beyond rituximab toward next-generation B-cell targeting (anifrolumab, obinutuzumab, telitacicept, others). Pursuit of "cure" rather than simply disease control. Understanding B-cell heterogeneity and different depletion/modulation strategies

Overall Vision: This congress represents rheumatology at an inflection point. The field is moving from a relatively simple paradigm (diagnose disease, suppress inflammation) to a sophisticated, multi-dimensional approach. The "next steps to the future" are not incremental improvements but fundamental transformations in how rheumatologists conceptualize disease, select treatments, and care for patients. This congress serves as both a roadmap and a call to action for the rheumatologic community to embrace this complexity and build the skills, knowledge, and collaborative networks necessary to deliver truly personalized, precision medicine to patients with rheumatic diseases.

Obiettivo Formativo: DOCUMENTAZIONE CLINICA. PERCORSI CLINICO-ASSISTENZIALI DIAGNOSTICI E RIABILITATIVI, PROFILI DI ASSISTENZA - PROFILI DI CURA (3)

Destinatari dell'iniziativa: 100 Medici Chirurghi specialisti in Medicina Interna, Reumatologia, Allergologia ed Immunologia Clinica, Malattie Apparato Respiratorio, Malattie infettive e tropicali

Mercoledì 20 maggio 2026

Welcome light lunch

Programma ECM

14.30 – 15.00 Apertura lavori: Giovanni Lapadula, Gianfranco Ferraccioli

Saluti istituzionali

Chairman: Florenzo Iannone, Roberto Caporali

15.00 – 15.30 Lettura Magistrale: From the Covid era to the post-Covid era! Pierluigi Lopalco

SESSION I

Title: Spondyloarthritis

Chairman: Leonardo Santo, Bruno Frediani, Angelo Semeraro

15.30 – 15.50 **From skin psoriasis to PsA: what pathogenetic mechanisms?**

Francesco Ciccia (Napoli)

15.50 – 16.10 **PsA interception in patient with psoriasis: true prevention or very early treatment of a subclinical disease?**

Ennio Giulio Favalli (Milano)

16.10 – 16.30 **From difficult-to-treat to difficult-to-manage PsA: definition and treatment of a complex entity**

Maria Sole Chimenti (Roma)

16.30 – 17.00 Discussion

17.00 – 17.30 Sponsor Lecture No ECM – Johnson&Johnson

Persistenza al trattamento in artrite psoriasica: cosa ci insegnano i dati di Guselkumab

Relatori: Maria Sole Chimenti, Elisa Gremese

Moderatori: Florenzo Iannone, Roberto Caporali.

17.30 – 18.00 Sponsor Lecture No ECM – Eli Lilly

Ixekizumab nella Real Life: il valore di un'efficacia bilanciata

Relatore: Andrea Delle Sedie

Moderatori: Serena Guiducci, Giuseppe Lopalco

18.00 – 19.00 Assemblea dei Centri GISEA Gruppo Italiano Studio Early Arthritis

Programma ECM

Giovedì 21 maggio 2026

SESSION II

Title: Rheumatoid Arthritis

Chairman: Fabrizio Conti (Roma), Rosario Foti, Costantino Pitzalis

09.00 – 09.20 When synovitis drives therapy

Elisa Gremese (Milano)

09.20 – 09.40 When serology drives therapy

Serena Bugatti (Pavia)

09.40 – 10.00 When comorbidities drive therapy

Florenzo Iannone (Bari)

10.00 – 10.30 Discussion

10.30 – 11.00 Coffee break

SESSION III

Title: Connective tissue disease (Miositi, Sjogren, SSc)

Chairman: Fabiola Atzeni (Messina), Francesco Paolo Cantatore, Francesca Romana Spinelli

11.00 – 11.20 Sjogren's unveiled: rethinking nomenclature in the era of targeted therapies

Michele Bombardieri (London)

11.20 – 11.40 Targeting Complexity: Novel Therapeutics and Subgroup Insights in Systemic Sclerosis

Marco Matucci-Cerinic (Milano)

11.40 – 12.00 Myositis on the Brink of a Revolution: New Therapies and the Power of Artificial Intelligence

Latika Gupta (Manchester)

12.00 – 12.30 Discussion

12.30 – 13.30 Lunch

Programma ECM

SESSION IV

Title: Comorbidities: obesity, ILD, infections and e profilaxis

Chairman: Marco Sebastiani (Parma), Fabio Cacciapaglia, Eleonora Bruschi

13.30- 13.50 How the obesity changes the management of rheumatic diseases, old drugs and new opportunity

of treatment

Roberto Caporali (Milano)

13.50 – 14.10 The management of rheumatoid arthritis related interstitial lung disease in light of new

international recommendations

Philippe Dieude (Parigi)

14.10 – 14.30 New drugs and old infections. Prophylaxis and vaccination in immunocompromised patients

Delia Goletti (Roma)

14.30 – 15.00 Discussion

15.00 – 15.30 Sponsor Lecture No ECM - Abbvie

Upadacitinib in RA & GCA: A way to achieve remission

Relatore: Corrado Campochiaro

Moderatore: Elisa Gremese

15.30 – 16.00 Sponsor Lecture No ECM – Eli Lilly

Il management del paziente con PsA e obesità

Relatore: Roberto Caporali

Moderatori: Florenzo Iannone

16.00 – 16.30 Sponsor Lecture No ECM – Boehringer Ingelheim

Nuove frontiere nelle complicanze polmonari in Reumatologia: come intercettare e gestire l'AR-ILD

Relatori: Marco Fornaro (Bari), Donato Lacedonia (Foggia)

Moderatore: Florenzo Iannone (Bari), Andereina Manfredi (Reggio Emilia)

16.30 – 17.00 Sponsor Lecture No ECM – UCB Pharma

Bimekizumab nelle spondiloartriti: evidenze e prospettive in PSA e AxSpA

Relatore: Giuseppe Lopalco

Moderatori: Salvatore D'Angelo, Ennio Lubrano

17.00 – 17.30 *Coffee break*

Venerdì 22 maggio 2026

Programma ECM

SESSIONE V

Title: Immune complexity in motion: SLE and Vasculitis towards precision care

Chairman: Elisa Gremese (Milano), Alberto Cauli, Roberta Ramonda

09.00 – 09.20 **B cells reloaded: evolution of a therapeutic target towards a cure for SLE**

Gianfranco Ferraccioli

09.20 – 09.40 **Difficult-to-treat SLE: recognition, prevention, and treatment approaches**

Matteo Piga (Cagliari)

09.40 – 10.00 **Redefining vasculitis from ANCA associated and EGPA to GCA: moving toward targeted, mechanism-driven approaches**

Roberto Padoan (Padova)

10.00 – 10.30 Discussion

10.30 – 11.00 *Coffee break*

11.00 – 11.30 Sponsor Lecture No ECM – Novartis

Secukinumab in PsA: Sustained Remission come obiettivo terapeutico

Relatore: Stefano Gentileschi

Moderatori: Francesco Paolo Cantatore

11.30 – 12.00 Sponsor Lecture No ECM – Alfasigma

Filgotinib in AR: dai trial clinici alla real-life

Relatore: Marco Sebastiani

Moderatori: Marco Fornaro, Ada Corrado

12.00 – 14.00 Lunch

14.00– 16.00 Sessione GISEA REGISTRY NO ECM

Safety and drug retention of bDMARDs and tsDMARDs

Chairmen: Roberto Caporali (Milano), Florenzo Iannone (Bari), Elisa Gremese (Milano)

14.00– 15.00 GISEA: one year in Review (comunicazioni di 5 min)

1. Cycling TNF Inhibitors or Switching to IL-17 Blockade in Axial Spondyloarthritis: Comparative Drug Survival in the GISEA Cohort

Relatore: A. Cito (Bari)

2. Comparative effectiveness and predictors of discontinuation of second-line immunosuppressive therapies for psoriatic arthritis: a GISEA Registry cohort study

Relatore: S. Gentileschi (Siena)

3. Perception of problematic disease management in rheumatoid arthritis patients

Relatore: M. Fornaro (Bari)

4. Real-world cancer incidence in rheumatoid arthritis patients receiving b/tsDMARDs: findings from the GISEA registry

Relatore: F. Atzeni (Messina)

5. Effectiveness, survival and prescription patterns of Janus kinase inhibitors in rheumatoid arthritis – results of a 5.9 year follow up from the Italian Study Group of Early Arthritis (GISEA) registry

Relatore: G. Cincinelli (Pini Milano)

6. Sex-based differences in 24-month treatment outcomes with b/ts-DMARDs in psoriatic arthritis: real-world evidence and predictive modeling from the Gruppo Italiano Studio Early Arthritis (GISEA) multicenter prospective registry

Relatore: S. Perniola (Bari)

7. Therapeutic strategies after JAK inhibitor failure: real-life data from the GISEA registry.

Relatore: C Garufi (Roma)

8. Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis: real world data from an Italian national registry.

Relatore: V Fiorilli (Roma)

9. Survival on therapy of certolizumab pegol in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: 8-year data from an Italian multicenter register.

Relatore: M. Manara (Milano)

15.00– 16.00 GISEA Registry: What's cooking in the pot? (comunicazioni di 3-5 minuti)

1. Risk factor–based screening for interstitial lung disease in rheumatoid arthritis: implications of the 2025 ERS/EULAR recommendations in the Italian GISEA Registry.

Relatore: A. Manfredi (Reggio Emilia)

2. Upadacitinib or anti-IL-17 after TNF Inhibitor Failure in Axial Spondyloarthritis: Real-World data from the Italian GISEA Registry.

Relatore: M. Fornaro (Bari)

3. Impatto dell'Inquinamento Atmosferico sulle Riacutizzazioni dell'Artrite Reumatoide.

Relatore: G. Adami (Verona), Marco Fornaro

4. Variation in the prescription patterns of biologics and targeted synthetic DMARDs among Italian rheumatologists over the years: identification of economic and clinical determinants.

Relatore: M Sebastiani (Parma)/ E Gremese (Milano)

5. Sex-based Prescription patterns in Psoriatic Arthritis and axial spondyloarthritis: data from the GISEA Registry

Relatore: MS Chimenti (Roma)

6. Complex-to-Manage and Treatment-Refractory Psoriatic Arthritis: prevalence, predictors and outcomes in the Italian GISEA Registry

Relatore: L. Cantarini (Siena)

Conclusions & next steps

FACULTY

Cognome/Nome	Laurea	Specializzazione	Attuale Posizione
Lapadula Giovanni	Medicina e Chirurgia	Reumatologia Medicina interna	Professore emerito Reumatologia Univ. Bari
Ferraccioli Gianfranco	Medicina e Chirurgia	Reumatologia Medicina interna	Professore emerito Reumatologia Univ. Cattolica Roma
Sebastiani Marco	Medicina e Chirurgia	Reumatologia	Professore Associato Dipartimento Chirurgico, Medico, Odontoiatrico e di Scienze Morfologiche con interesse Trapiantologico, Oncologico e di Medicina Rigenerativa UniMore Modena/Reggio Emilia
Padoan Roberto	Medicina e Chirurgia	Reumatologia	Azienda Ospedaliero Universitaria di Padova
Favalli Ennio Giulio	Medicina e Chirurgia	Reumatologia	Prof a Contratto Università degli studi di Milano
Chimenti Maria Sole	Medicina e Chirurgia	Reumatologia	Prof.ssa Associata Università di Roma Tor Vergata
Cauli Alberto	Medicina e Chirurgia	Reumatologia	Prof. Ordinario Università di Cagliari
Conti Fabrizio	Medicina e Chirurgia	Medicina Interna	Professore Associato di Reumatologia, Dipartimento di Medicina Interna e Specialità Mediche, Sapienza Università di Roma.
Gremese Elisa	Medicina e Chirurgia	Medicina Interna Reumatologia	Prof. Associato Reumatologia Università di Milano
Bugatti Serena	Medicina e Chirurgia	Reumatologia	Ricercatore Istituto Di Reumatologia Università di Pavia

Pitzalis Costantino	Medicina e Chirurgia	Reumatologia	Prof. Ordinario Reumatologia Humanitas University Rozzano - Milano
Atzeni Fabiola	Medicina e Chirurgia	Reumatologia	Prof. Ordinario reumatologia Università di Messina
Iannone Florenzo	Medicina e Chirurgia	Reumatologia	Prof. Ordinario Reumatologia Università di Bari
Ramonda Roberta	Medicina e Chirurgia	Reumatologia	Prof. Ordinario Università di Padova
Matucci Cerinic Marco	Medicina e Chirurgia	Reumatologia	Professore Ordinario di Reumatologia presso Università di Firenze
Caporali Roberto	Medicina e Chirurgia	Reumatologia	Prof. Ordinario Università di Milano
Semeraro Angelo	Medicina e Chirurgia	Reumatologia	Direttore U.O. Reumatologia Ambulatoriale Ospedale Martina Franca-Taranto
Frediani Bruno	Medicina e Chirurgia	Reumatologia	Prof. Ordinario Reumatologia univeità di Siena
Santo Leonardo	Medicina e Chirurgia	Reumatologia	Direttore U.O. Reumatologia Ospedale Barletta
Foti Rosario	Medicina e Chirurgia	Reumatologia	Direttore U.O. Reumatologia Ospedale Rodolico San Marco - Catania
Cantatore Francesco Paolo	Medicina e Chirurgia	Reumatologia	Direttore dell'Unità Complessa di Reumatologia dell'Azienda Mista Ospedale- Università. "Ospedali Riuniti" di Foggia
Lopalco Pierluigi	Medicina e Chirurgia	Igiene e Medicina preventiva	Full Professor of Hygiene and Preventive Medicine at University of Pisa

Ciccia Francesco	Medicina e Chirurgia	Reumatologia	Prof. Ordinario reumatologia presso Università L. Vanvitelli Napoli
Spinelli Francesca Romana	Medicina e Chirurgia	Reumatologia	Prof. Associato reumatologia Univ. La Sapienza Roma
Bombardieri Michele	Medicina e Chirurgia	Reumatologia	Professore presso Queen Mary University of London
Gupta Latika	Medicina e Chirurgia	Reumatologia	prof. associato presso University of Birmingham (UK)
Cacciapaglia Fabio	Medicina e Chirurgia	Reumatologia	Prof. Associato reumatologia presso Università LUM – Casamassima (Bari)
Bruschi Eleonora	Medicina e Chirurgia	Reumatologia	Dirigente medico I livello presso Ospedale di Bergamo
Dieude Philippe	Medicina e Chirurgia	Reumatologia	Professore presso l'Université Paris Cité.
Goletti Delia	Medicina e Chirurgia	Malattie infettive e tropicali	dirigente medico presso spallanzani Roma
Ferraccioli Gianfranco	Medicina e Chirurgia	Reumatologia	Prof. Ordinario in quiescenza, attualmente reumatologo presso Udine
Piga Matteo	Medicina e Chirurgia	Reumatologia	Professore Associato di Reumatologia univ. Di Cagliari

La sottoscritta Susanna Priore, nata a Lecce il 13/03/1965 C.F. PRRSNN65C53E506S ed ivi residente in via Potenza 19, in qualità di Legale Rappresentante di FORMEDICA S.R.L. (Provider Ministeriale n. 157) dichiara sotto la propria responsabilità che i curricula dei Relatori/Moderatori relativi all'evento: **GISEA/OEG INTERNATIONAL SYMPOSIUM 2026 Rheumatology and complex diseases: next steps to the future 20-21-22 MAGGIO 2026 Palazzo San Giorgio – Trani** avendo un peso superiore ai 4 MB non possono essere inseriti nel campo apposito, pertanto sono disponibili presso gli archivi della nostra sede legale.